- Meeting abstract
- Open Access
cGMP and cardiac hypertrophy
BMC Pharmacology and Toxicology volume 16, Article number: A12 (2015)
cGMP as a second messenger regulates cardiac contractility and might protect the heart from hypertrophy and failure by acting in distinct subcellular microdomains. However, direct visualization of cGMP in subcellular microdomains of adult cardiomyocytes has been challenging. Little is known also about changes in cardiomyocyte cGMP signalling at an early stage of the disease.
We used a highly sensitive cytosolic and membrane-targeted Förster resonance energy transfer (FRET)-based biosensors for cGMP and cAMP for real time measurements in freshly isolated sensor-trasngenic adult ventricular cardiomyocytes. Combined with single cell contractility measurements, biochemical techniques and whole-heart recording, the effect of atrial natriuretic peptide (ANP) on cardiomyocyte cGMP/cAMP and contractility in healthy and hypertrophied hearts (after transverse aortic constriction).
Contractility measurements in hypertrophied hearts have unravelled ANP-induced augmentation of catecholamine stimulated increase in force and frequency of contraction which was present only in diseased hearts at the state of early compensated cardiac hypertrophy. Interestingly, this effect was not due to changes in cGMP content, membrane receptor densities or whole-cells phosphodiesterase (PDE) activity. Instead, physical redistribution of the cGMP-stimulated PDE2 and cGMP-inhibited PDE3 between distinct membrane domains led to a change of cAMP compartmentation towards an ANP/cGMP/PDE3-dependent increase of local cAMP levels in a microdomain regulating cardiac contractility . FRET-based cGMP measurements revealed relatively small increase of cGMP upon ANP stimulation , stringent compartmentation of ANP/cGMP signals to T-tubular membranes and apparent absence of receptor desensitization in early cardiac hypertrophy .
ANP/cGMP signalling can play distinct roles in cardiac disease, including a previously unrecognized contractility augmentation in early hypertrophy which might support heart function upon pressure overload. This can be achieved by PDE2/3 redistribution-dependent changes in cGMP/cAMP compartmentation.
Perera RK, et al: Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ Res. 2015, 116: 1304-1311. 10.1161/CIRCRESAHA.116.306082.
Götz KR, et al: Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes. Circ Res. 2014, 114: 1235-1245. 10.1161/CIRCRESAHA.114.302437.
About this article
Cite this article
Perera, R.K., Subramanian, H., Froese, A. et al. cGMP and cardiac hypertrophy. BMC Pharmacol Toxicol 16, A12 (2015). https://doi.org/10.1186/2050-6511-16-S1-A12
- Cardiac Hypertrophy
- Atrial Natriuretic Peptide
- Cardiac Contractility
- Transverse Aortic Constriction
- Hypertrophied Heart